These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 33467196)

  • 1. The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia.
    Nyffenegger N; Flace A; Doucerain C; Dürrenberger F; Manolova V
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers.
    Richard F; van Lier JJ; Roubert B; Haboubi T; Göhring UM; Dürrenberger F
    Am J Hematol; 2020 Jan; 95(1):68-77. PubMed ID: 31674058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia.
    Manolova V; Nyffenegger N; Flace A; Altermatt P; Varol A; Doucerain C; Sundstrom H; Dürrenberger F
    J Clin Invest; 2019 Dec; 130(1):491-506. PubMed ID: 31638596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development.
    Porter J; Taher A; Viprakasit V; Kattamis A; Coates TD; Garbowski M; Dürrenberger F; Manolova V; Richard F; Cappellini MD
    Expert Rev Hematol; 2021 Jul; 14(7):633-644. PubMed ID: 34324404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
    Lin CH; Chen X; Wu CC; Wu KH; Song TS; Weng TF; Hsieh YW; Peng CT
    Expert Rev Hematol; 2019 Apr; 12(4):265-272. PubMed ID: 30920854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions.
    Kalleda N; Flace A; Altermatt P; Ingoglia G; Doucerain C; Nyffenegger N; Dürrenberger F; Manolova V
    Haematologica; 2023 Oct; 108(10):2703-2714. PubMed ID: 37165842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia.
    Schmidt PJ; Racie T; Westerman M; Fitzgerald K; Butler JS; Fleming MD
    Am J Hematol; 2015 Apr; 90(4):310-3. PubMed ID: 25557851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia.
    Vadolas J; Ng GZ; Kysenius K; Crouch PJ; Dames S; Eisermann M; Nualkaew T; Vilcassim S; Schaeper U; Grigoriadis G
    Br J Haematol; 2021 Jul; 194(1):200-210. PubMed ID: 33942901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin.
    Gardenghi S; Marongiu MF; Ramos P; Guy E; Breda L; Chadburn A; Liu Y; Amariglio N; Rechavi G; Rachmilewitz EA; Breuer W; Cabantchik ZI; Wrighting DM; Andrews NC; de Sousa M; Giardina PJ; Grady RW; Rivella S
    Blood; 2007 Jun; 109(11):5027-35. PubMed ID: 17299088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA; Hamam MA; Taha OA; Hazaa SM
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of heme oxygenase ameliorates anemia and reduces iron overload in a β-thalassemia mouse model.
    Garcia-Santos D; Hamdi A; Saxova Z; Fillebeen C; Pantopoulos K; Horvathova M; Ponka P
    Blood; 2018 Jan; 131(2):236-246. PubMed ID: 29180398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy And Tolerability Of Oral Iron Chelator, Deferasirox.
    Tahir A; Hussain SI; Khan HS; Khalil S; Haider SZ; Lodhi MA
    J Ayub Med Coll Abbottabad; 2021; 33(2):207-212. PubMed ID: 34137530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
    Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S
    Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
    Chen CH; Shu KH; Yang Y
    Hematology; 2015 Jun; 20(5):304-10. PubMed ID: 25200910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis.
    Dou H; Qin Y; Chen G; Zhao Y
    Acta Haematol; 2019; 141(1):32-42. PubMed ID: 30504715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal function in β-thalassemia major patients treated with two different iron-chelation regimes.
    Tanous O; Azulay Y; Halevy R; Dujovny T; Swartz N; Colodner R; Koren A; Levin C
    BMC Nephrol; 2021 Dec; 22(1):418. PubMed ID: 34930156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia.
    Casu C; Aghajan M; Oikonomidou PR; Guo S; Monia BP; Rivella S
    Haematologica; 2016 Jan; 101(1):e8-e11. PubMed ID: 26405152
    [No Abstract]   [Full Text] [Related]  

  • 20. Effectiveness and tolerability of twice daily dosing of deferasirox in unresponsive and intolerant transfusion-dependent beta-thalassemia patients: A narrative review.
    Babu T; Panachiyil GM; Sebastian J; Ravi MD
    Indian J Pharmacol; 2020; 52(6):514-519. PubMed ID: 33666193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.